We investigated the effect of fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, on insulin sensitivity including lipid metabolism in skeletal muscle. Six-week-old male Sprague-Dawley rats were divided into two groups: those fed a standard chow (control) or a fructose-rich chow (fructose-fed rats (FFRs)) for 6 weeks. FFRs were treated either with a vehicle or with 30 mg/kg...

BACKGROUND The Diabetes Atherosclerosis Intervention Study showed that treatment with fenofibrate decreases progression of coronary atherosclerosis in subjects with type 2 diabetes. We determined whether on-treatment plasma lipid concentrations and LDL particle size contribute to the favorable effect of fenofibrate on the progression of coronary artery disease (CAD). METHODS AND RESULTS A tot...

BACKGROUND Peroxisome proliferator-activated receptor-alpha (PPAR-alpha) is a lipid-activated nuclear receptor that negatively regulates the vascular inflammatory gene response by interacting with transcription factors, nuclear factor-kappaB, and AP-1. However, the roles of PPAR-alpha activators in endothelin (ET)-1-induced cardiac hypertrophy are not yet known. METHODS AND RESULTS First, in ...

Rodent studies suggest that peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation reduces myocardial ischemia-reperfusion (I/R) injury and infarct size; however, effects of PPAR-alpha activation in large animal models of myocardial I/R are unknown. We determined whether chronic treatment with the PPAR-alpha activator fenofibrate affects myocardial I/R injury in pigs. Domestic...

The National Cholesterol Education Program (NCEP) guidelines recommend use of statin-fibrate combinations to treat combined dyslipidemia. Myopathy and rhabdomyolysis are reported side effects, especially with gemfibrozil-statin combinations (1). This risk is recognized to result from both pharmacodynamic and pharmacokinetic interactions. In vitro studies in human hepatocytes have shown that unl...

AIM The aim of our study is to elucidate the effects of EPA- or DHA-rich fish oil, and of the latter plus fenofibrate, on lipid metabolism in female KK mice. METHODS Female KK mice were fed purified experimental diets containing lard/safflower oil (4:6, Lard/SO), EPA-rich fish oil (EPA), DHA-rich fish oil (DHA), or DHA-rich fish oil plus 0.2% (w/w) fenofibrate (DHA+FF) for 8 weeks. At the end...

Background Several agents have been used for the treatment of neonatal hyperbilirubinemia, but the effect of oral fenofibrate on serum bilirubin level was not evaluated so much. The aim of this study was to assess the effect of oral fenofibrate on a total serum bilirubin (TSB) in term neonates with hyperbilirubinemia. Materials and Methods: This clinical trial was done on 80 term neonate with ...

Objectives The aim of this study was to determine the effects of fenofibrate (160 mg/d) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome. Research Design and Methods Fifty-nine subjects with fasting hypertriglyceridemia (≥1.7 mmol/L and <6.9 mmol/L) and two or more of the Adult Treatment P...

Diabetes mellitus is strongly connected with changes in lipid profile and also can cause damage of several organs like liver over a long period of time. The purpose of this study was designed to evaluate the hypolipidemic and hepatoprotective effects of ethanolic root extracts of Asparagus racemosus (EEAR) Linn. alone and in combination with a lipid lowering agent (fenofibrate) in alloxan-induc...

Fibrates and statins have been widely used to reduce triglyceride cholesterol levels, respectively. Besides its lipid-lowering effect, the side effect of muscle atrophy after fibrate administration humans has demonstrated in some studies. Combination therapy with fibrates also increases risk rhabdomyolysis. FoxO1, a member FoxO forkhead type transcription factor family, is markedly upregulated ...